Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: Is this of concern?

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 4057-4062

  Monnier, Louis ^a   Colette, Claude ^a   Dejager, Sylvie ^b   Owens, David ^c  

^a UNIV MONTPELLIER   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; COMPARATIVE STUDY; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; BLOOD; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIET; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; RETROSPECTIVE STUDY; TIME;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84891878975     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2127     Document Type: Article

References (23)

1. Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981;4:579-585
2. Schmidt MI, Lin QX, Gwynne JT, Jacobs S. Fasting early morning rise in peripheral insulin: evidence of the dawn phenomenon in nondiabetes. Diabetes Care 1984; 7:32-35
3. Buckingham B, Black J, Wilson DM. Continuous glucose monitoring. Curr Opin Endocrinol Diabetes 2005;12:273-279
4. Skyler JS. Continuous glucose monitoring: an overview of its development. Diabetes Technol Ther 2009;11(Suppl. 1): S5-S10
5. Bolli GB, Gerich JE. The "dawn phenomenon"da common occurrence in both non-insulin-dependent and insulindependent diabetes mellitus. N Engl J Med 1984;310:746-750
6. Atiea JA, Luzio S, Owens DR. The dawn phenomenon and diabetes control in treated NIDDM and IDDM patients. Diabetes Res Clin Pract 1992;16:183-190
7. Carroll MF, Hardy KJ, Burge MR, Schade DS. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. Diabetes Technol Ther 2002;4:595-605
8. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005;11:55-64
9. Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D. Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age. Diabetes Care 2012;35:2597-2599
10. Schofield WN, Schofield C, James WPT. Basal metabolic ratedreview and prediction, together with an annotated bibliography of source material. Hum Nutr Clin Nutr 1985;39C(Suppl. 1):1-96
11. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926
12. Directive 2001/20/CE of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical trials on medicinal products for human use. Off J Eur Communities 2001;L121:33-44
13. 1c measurements be reported? Diabetologia 2006;49:7-10
14. Sacks DB, Bruns DE, Goldstein DE, MacLaren NK, McDonald JM, Parrott M. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement). Diabetes Care 2002;25: 750-786
15. Sacks DB. Measurement of hemoglobin A1c: a new twist on the path to harmony. Diabetes Care 2012;35:2674-2680
16. Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002;25:889-893
17. Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 1999;22:394-398
18. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25:737-741
19. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-269
20. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996;45:1044-1050
21. Perriello G, Pampanelli S, Del Sindaco P, et al. Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. Diabetes 1997; 46:1010-1016
22. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose (ADAG) Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478
23. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596